Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
NCT05001880 · View on ClinicalTrials.gov ↗
Study Summary
This phase II trial compares the usual treatment alone (carboplatin, pemetrexed, and bevacizumab) to using immunotherapy (atezolizumab) plus the usual treatment in treating patients with peritoneal mesothelioma. The usual treatment consists of surgery or chemotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid and may kill cancer cells. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab with usual treatment may work better than usual treatment alone.
Conditions Studied
Interventions
- DRUG Carboplatin
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- BIOLOGICAL Atezolizumab
- BIOLOGICAL Bevacizumab
Study Locations (20)
Minnesota
- Sanford Joe Lueken Cancer Center — Bemidji
- Mercy Hospital — Coon Rapids
- Fairview Southdale Hospital — Edina
- Unity Hospital — Fridley
- Abbott-Northwestern Hospital — Minneapolis
- Mayo Clinic in Rochester — Rochester
- Park Nicollet Clinic - Saint Louis Park — Saint Louis Park
- Regions Hospital — Saint Paul
- United Hospital — Saint Paul
- Rice Memorial Hospital — Willmar
- Sanford Cancer Center Worthington — Worthington
Illinois
- Alliance for Clinical Trials in Oncology — Chicago
- University of Chicago Comprehensive Cancer Center — Chicago
- Carle at The Riverfront — Danville
- Carle Physician Group-Effingham — Effingham
- Carle Physician Group-Mattoon/Charleston — Mattoon
- Carle Cancer Center — Urbana
- The Carle Foundation Hospital — Urbana
Arizona
- Mayo Clinic Hospital in Arizona — Phoenix
Kentucky
- University of Kentucky/Markey Cancer Center — Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2022-03-22 |
| Est. Completion | 2026-08-20 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05001880
The ClinicalTrials.gov registry entry for NCT05001880 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 2,390 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Peritoneal Malignant Mesothelioma appearing as the primary indexed condition, and to 5 interventions — of which Carboplatin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05001880 reports 20 study locations spanning 4 distinct geographic areas — top geographies include Minnesota, Illinois, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05001880 about?
NCT05001880 is a clinical study titled "Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma". This phase II trial compares the usual treatment alone (carboplatin, pemetrexed, and bevacizumab) to using immunotherapy (atezolizumab) plus the usual treatment in treating patients with peritoneal mesothelioma. The usual treatment consists of surgery or chemotherapy. Carboplatin is in a class of me...
What is the current status of trial NCT05001880?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2022-03-22. Estimated completion is 2026-08-20.
What conditions does trial NCT05001880 study?
This clinical trial studies the following conditions: Peritoneal Malignant Mesothelioma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05001880?
The interventions under investigation include: Carboplatin (DRUG), Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Atezolizumab (BIOLOGICAL), Bevacizumab (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05001880?
This trial is sponsored by National Cancer Institute (NCI), which has 2,390 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05001880 being conducted?
This trial has 20 study locations across Arizona, Illinois, Kentucky, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.